| Expression pattern: |
DN |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
May serve as a stable, noninvasive plasma biomarker and part of a diagnostic panel for early-stage NSCLC. |
| Molecular mechanism: |
circCAMTA1 is generated by splicing of CAMTA1 exons 5, 7, and 9 and exhibits RNase R resistance and longer half-life than CAMTA1 mRNA, supporting structural stability as a circular RNA biomarker. |
| Biological pathway or process: |
not specified |
| Detected method: |
Q
S
|
| Validation methods: |
Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; circRNA-seq; Clinical Sample Validation; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
Downregulated circCAMTA1 is significantly associated with TNM staging and may serve as a diagnostic biomarker for early-stage NSCLC, especially in combination with circALG8 and traditional tumor markers. |
| Description: |
circCAMTA1 is a human CAMTA1-derived circular RNA that is downregulated in NSCLC tumor tissues and plasma. The study validates its circular stability and supports its use as a noninvasive diagnostic biomarker, particularly as part of a plasma circALG8/circCAMTA1 panel for early-stage NSCLC. |
| Confidence score: |
0.6676 |